Assessment of systemic AAV-microdystrophin gene therapy in the GRMD model of Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease caused by the absence of dystrophin, a membrane-stabilizing protein encoded by the DMD gene. Although mouse models of DMD provide insight into the potential of a corrective therapy, data from genetically homologous large animals, such as the dystrophin-deficient golden retriever muscular dystrophy (GRMD) model, may more readily translate to humans. To evaluate the clinical translatability of an adeno-associated virus serotype 9 vector (AAV9)-microdystrophin (µDys5) construct, we performed a blinded, placebo-controlled study in which 12 GRMD dogs were divided among four dose groups [control, 1 × 1013 vector genomes per kilogram (vg/kg), 1 × 1014 vg/kg, and 2 × 1014 vg/kg; n = 3 each], treated intravenously at 3 months of age with a canine codon-optimized microdystrophin construct, rAAV9-CK8e-c-µDys5, and followed for 90 days after dosing. All dogs received prednisone (1 milligram/kilogram) for a total of 5 weeks from day -7 through day 28. We observed dose-dependent increases in tissue vector genome copy numbers; µDys5 protein in multiple appendicular muscles, the diaphragm, and heart; limb and respiratory muscle functional improvement; and reduction of histopathologic lesions. As expected, given that a truncated dystrophin protein was generated, phenotypic test results and histopathologic lesions did not fully normalize. All administrations were well tolerated, and adverse events were not seen. These data suggest that systemically administered AAV-microdystrophin may be dosed safely and could provide therapeutic benefit for patients with DMD.

Spike-and-slab type variable selection in the Cox proportional hazards model for high-dimensional features.

In this paper, we develop a variable selection framework with the spike-and-slab prior distribution via the hazard function of the Cox model. Specifically, we consider the transformation of the score and information functions for the partial likelihood function evaluated at the given data from the parameter space into the space generated by the logarithm of the hazard ratio. Thereby, we reduce the nonlinear complexity of the estimation equation for the Cox model and allow the utilization of a wider variety of stable variable selection methods. Then, we use a stochastic variable search Gibbs sampling approach via the spike-and-slab prior distribution to obtain the sparsity structure of the covariates associated with the survival outcome. Additionally, we conduct numerical simulations to evaluate the finite-sample performance of our proposed method. Finally, we apply this novel framework on lung adenocarcinoma data to find important genes associated with decreased survival in subjects with the disease.

Impact of Demographic and Obstetric Factors on Infant Brain Volumes: A Population Neuroscience Study.

Individual differences in neuroanatomy are associated with intellectual ability and psychiatric risk. Factors responsible for this variability remain poorly understood. We tested whether 17 major demographic and obstetric variables were associated with individual differences in brain volumes in 756 neonates assessed with MRI. Gestational age at MRI, sex, gestational age at birth, and birthweight were the most significant predictors, explaining 31% to 59% of variance. Unexpectedly, earlier born babies had larger brains than later born babies after adjusting for other predictors. Our results suggest earlier born children experience accelerated brain growth, either as a consequence of the richer sensory environment they experience outside the womb or in response to other factors associated with delivery. In the full sample, maternal and paternal education, maternal ethnicity, maternal smoking, and maternal psychiatric history showed marginal associations with brain volumes, whereas maternal age, paternal age, paternal ethnicity, paternal psychiatric history, and income did not. Effects of parental education and maternal ethnicity are partially mediated by differences in birthweight. Remaining effects may reflect differences in genetic variation or cultural capital. In particular late initiation of prenatal care could negatively impact brain development. Findings could inform public health policy aimed at optimizing child development.

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Alemtuzumab (anti-CD52 mAb) provides long-lasting disease activity suppression in relapsing-remitting multiple sclerosis (RRMS). The objective of this study was to characterize the immunological reconstitution of T cell subsets and its contribution to the prolonged RRMS suppression following alemtuzumab-induced lymphocyte depletion. The study was performed on blood samples from RRMS patients enrolled in the CARE-MS II clinical trial, which was recently completed and led to the submission of alemtuzumab for U.S. Food and Drug Administration approval as a treatment for RRMS. Alemtuzumab-treated patients exhibited a nearly complete depletion of circulating CD4(+) lymphocytes at day 7. During the immunological reconstitution, CD4(+)CD25(+)CD127(low) regulatory T cells preferentially expanded within the CD4(+) lymphocytes, reaching their peak expansion at month 1. The increase in the percentage of TGF-ß1-, IL-10-, and IL-4-producing CD4(+) cells reached a maximum at month 3, whereas a significant decrease in the percentages of Th1 and Th17 cells was detected at months 12 and 24 in comparison with the baseline. A gradual increase in serum IL-7 and IL-4 and a decrease in IL-17A, IL-17F, IL-21, IL-22, and IFN-γ levels were detected following treatment. In vitro studies have demonstrated that IL-7 induced an expansion of CD4(+)CD25(+)CD127(low) regulatory T cells and a decrease in the percentages of Th17 and Th1 cells. In conclusion, our results indicate that differential reconstitution of T cell subsets and selectively delayed CD4(+) T cell repopulation following alemtuzumab-induced lymphopenia may contribute to its long-lasting suppression of disease activity.